צמיחת מכירות ב-12 חודשים נגררים: plustherapeutics.com (PSTV)

Stable demand for biotechnology protects Plus Therapeutics, Inc. (PSTV) from recessions, serving as the primary driver of its price action. The historical year-over-year revenue growth trend over the last 12 months confirms the business's resilience, where -0.50 captures the current state of the parameter. The model relies on external CDMO plants in Texas, while the sale of isotopes for radiotherapy systems ensures a steady cash flow.
Plus Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (PSTV)

Plus Therapeutics, Inc. (PSTV) maintains a dominant position in radiopharmaceuticals due to the uniqueness of its Rhenium-186 NanoLiposome drug and inelastic demand. This indicator captures the percentage change in rolling annual revenue with a daily update of the calculation series. Investors utilize this tool to analyze the business model's resilience to macroeconomic shocks. The issuer's strong pricing power should be reflected in the steady growth of these metrics. By analyzing the 12-month year-over-year revenue dynamics, one can assess the company's actual market expansion.